VERO Fundamental Analysis - VENUS CONCEPT INC

Name: VENUS CONCEPT INC (VERO) Stock
Brand: VENUS CONCEPT INC
Rating: 2 (3 reviews)

Fundamental Rating

Overall VERO gets a fundamental rating of 1 out of 10. We evaluated VERO against 189 industry peers in the Health Care Equipment & Supplies industry. VERO has a bad profitability rating. Also its financial health evaluation is rather negative. VERO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

VERO had negative earnings in the past year.

In the past year VERO has reported a negative cash flow from operations.

VERO had negative earnings in each of the past 5 years.

In the past 5 years VERO always reported negative operating cash flow.

1.2 Ratios

VERO has a worse Return On Assets (-65.52%) than 71.43% of its industry peers.

VERO has a Return On Equity of -1776.32%. This is amonst the worse of the industry: VERO underperforms 88.89% of its industry peers.

		Industry Rank	Sector Rank
ROA	-65.52%
ROE	-1776.32%
ROIC	N/A

ROA(3y)-47.85%

ROA(5y)-42.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VERO has a Gross Margin of 64.88%. This is in the better half of the industry: VERO outperforms 68.78% of its industry peers.

In the last couple of years the Gross Margin of VERO has remained more or less at the same level.

VERO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	64.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.88%

GM growth 5Y-0.33%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.

VERO has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, VERO has more shares outstanding

The debt/assets ratio for VERO has been reduced compared to a year ago.

2.2 Solvency

VERO has an Altman-Z score of -8.02. This is a bad value and indicates that VERO is not financially healthy and even has some risk of bankruptcy.

VERO has a worse Altman-Z score (-8.02) than 73.02% of its industry peers.

A Debt/Equity ratio of 6.82 is on the high side and indicates that VERO has dependencies on debt financing.

The Debt to Equity ratio of VERO (6.82) is worse than 88.36% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	6.82
Debt/FCF	N/A
Altman-Z	-8.02

ROIC/WACCN/A

WACC2.96%

2.3 Liquidity

VERO has a Current Ratio of 1.10. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.10, VERO is not doing good in the industry: 87.30% of the companies in the same industry are doing better.

A Quick Ratio of 0.71 indicates that VERO may have some problems paying its short term obligations.

With a Quick ratio value of 0.71, VERO is not doing good in the industry: 87.30% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.1
Quick Ratio	0.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.91% over the past year.

VERO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.90%.

Measured over the past years, VERO shows a very negative growth in Revenue. The Revenue has been decreasing by -10.10% on average per year.

EPS 1Y (TTM)44.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.07%

Revenue 1Y (TTM)-13.9%

Revenue growth 3Y-15.01%

Revenue growth 5Y-10.1%

Sales Q2Q%-5.37%

3.2 Future

The Earnings Per Share is expected to grow by 39.27% on average over the next years. This is a very strong growth

The Revenue is expected to decrease by -0.18% on average over the next years.

EPS Next Y76.72%

EPS Next 2Y39.27%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-9.41%

Revenue Next 2Y-0.18%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VERO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VERO's earnings are expected to grow with 39.27% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.27%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VERO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VENUS CONCEPT INC

NASDAQ:VERO (11/7/2025, 8:24:37 PM)

1.93

-0.07 (-3.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-13 2025-11-13/bmo

Inst Owners13.23%

Inst Owner Change0%

Ins Owners0.78%

Ins Owner Change0%

Market Cap3.59M

Revenue(TTM)60.11M

Net Income(TTM)-41.34M

Analysts45.71

Price TargetN/A

Short Float %5.59%

Short Ratio0.99

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-20.91%

Min EPS beat(2)-21.43%

Max EPS beat(2)-20.38%

EPS beat(4)0

Avg EPS beat(4)-14.09%

Min EPS beat(4)-21.43%

Max EPS beat(4)-4.58%

EPS beat(8)0

Avg EPS beat(8)-30.66%

EPS beat(12)2

Avg EPS beat(12)-21.75%

EPS beat(16)3

Avg EPS beat(16)-28.76%

Revenue beat(2)1

Avg Revenue beat(2)0.46%

Min Revenue beat(2)-4.4%

Max Revenue beat(2)5.33%

Revenue beat(4)1

Avg Revenue beat(4)-5.75%

Min Revenue beat(4)-14.85%

Max Revenue beat(4)5.33%

Revenue beat(8)2

Avg Revenue beat(8)-5.83%

Revenue beat(12)4

Avg Revenue beat(12)-3.95%

Revenue beat(16)5

Avg Revenue beat(16)-4.49%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)4.87%

EPS NY rev (1m)-1.85%

EPS NY rev (3m)5.72%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-1.42%

Revenue NY rev (1m)0%

Revenue NY rev (3m)1.44%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.06
P/FCF	N/A
P/OCF	N/A
P/B	1.54
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-50.78

EYN/A

EPS(NY)-4.67

Fwd EYN/A

FCF(TTM)-10.15

FCFYN/A

OCF(TTM)-10.01

OCFYN/A

SpS32.32

BVpS1.25

TBVpS-0.5

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-65.52%
ROE	-1776.32%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	64.88%
FCFM	N/A

ROA(3y)-47.85%

ROA(5y)-42.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.88%

GM growth 5Y-0.33%

F-Score4

Asset Turnover0.95

Health

		Industry Rank	Sector Rank
Debt/Equity	6.82
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	7.11%
Cap/Sales	0.45%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.1
Quick Ratio	0.71
Altman-Z	-8.02

F-Score4

WACC2.96%

ROIC/WACCN/A

Cap/Depr(3y)4.54%

Cap/Depr(5y)6.03%

Cap/Sales(3y)0.23%

Cap/Sales(5y)0.31%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)44.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.07%

EPS Next Y76.72%

EPS Next 2Y39.27%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-13.9%

Revenue growth 3Y-15.01%

Revenue growth 5Y-10.1%

Sales Q2Q%-5.37%

Revenue Next Year-9.41%

Revenue Next 2Y-0.18%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-16.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year67.6%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-22.17%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-21.82%

OCF growth 3YN/A

OCF growth 5YN/A

VENUS CONCEPT INC / VERO FAQ

What is the ChartMill fundamental rating of VENUS CONCEPT INC (VERO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to VERO.

What is the valuation status for VERO stock?

ChartMill assigns a valuation rating of 1 / 10 to VENUS CONCEPT INC (VERO). This can be considered as Overvalued.

Can you provide the profitability details for VENUS CONCEPT INC?

VENUS CONCEPT INC (VERO) has a profitability rating of 1 / 10.

Can you provide the financial health for VERO stock?

The financial health rating of VENUS CONCEPT INC (VERO) is 1 / 10.

VENUS CONCEPT INC (VERO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VENUS CONCEPT INC / VERO FAQ

What is the ChartMill fundamental rating of VENUS CONCEPT INC (VERO) stock?

What is the valuation status for VERO stock?

Can you provide the profitability details for VENUS CONCEPT INC?

Can you provide the financial health for VERO stock?